USPTO serial 97893946
CELLARITYX
Reviewed by CopyMark Law Group
Status 734Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- CRAVEN, PAUL S
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with CELLARITYX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,246*
Plus Government fees of $600
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Somerville, MA, US
Somerville, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christina M. Licursi
Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210-2206United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders | ACTIVE | — |
| 009 | Downloadable computer software involving the use of artificial intelligence technology for molecular design | ACTIVE | — |
| 042 | Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; drug development and discovery; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services for scientific research purposes, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable computer software involving the use of artificial intelligence technology for molecular design; scientific diagnostic and screening services, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug development; providing on-line non-downloadable software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for data analysis in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing on-line non-downloadable software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks | ACTIVE | — |
| 044 | Medical diagnostic and screening services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cellarity, Inc.
- Other trademarks owned by Cellarity, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CELLARITYX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 10, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 10, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 9, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 29, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jul 29, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 12, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 12, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 12, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 12, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 9, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 8, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 8, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 8, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 10, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 10, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 10, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 10, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 9, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 9, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 9, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 9, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 13, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 19, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 19, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 29, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 16, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 2, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 2, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 2, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 7, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 7, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 7, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 21, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 12, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |